The Future Landscape: Topical vs. Systemic JAK Inhibitors in Vitiligo

In the final episode, ‘The Future Landscape: Topical vs. Systemic JAK Inhibitors in Vitiligo ,’ the panelists explored the following critical questions:

How do you envision the treatment landscape changing with the introduction of oral JAK inhibitors?

How will you decide oral vs. topical JAK inhibitors?

The expert dermatologist examined the clinical differentiation between topical and systemic JAK inhibitors, noting that oral agents are particularly suitable for patients with large body surface area (BSA), numerous small lesions, or rapidly progressive disease. While all JAK inhibitors carry class warnings for serious adverse events (AEs), Dr. Rosmarin highlighted that the vitiligo population may have a lower underlying risk for these events compared to other autoimmune populations. He emphasized that topical JAK inhibitors have demonstrated a favorable safety profile in clinical practice, while the upcoming oral options will complete the clinician's armamentarium for managing more extensive disease.

Please be sure to stay tuned for additional videos in this Population Health Perspectives series!